Company Encyclopedia
View More
name
Beam Therapeutics
BEAM.US
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
1.946 T
BEAM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking198/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-47.19%E
    • Profit Margin-744.41%E
    • Gross Margin-1031.87%E
  • Growth ScoreE
    • Revenue YoY-84.07%E
    • Net Profit YoY-188.77%E
    • Total Assets YoY11.93%B
    • Net Assets YoY22.08%A
  • Cash ScoreE
    • Cash Flow Margin-13.43%D
    • OCF YoY-84.07%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreB
    • Gearing Ratio26.32%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    14,601 Shares in Beam Therapeutics Inc. $BEAM Bought by Entropy Technologies LP

    Entropy Technologies LP acquired 14,601 shares of Beam Therapeutics, valued at $248,000. Institutional investors like Price T Rowe and Vanguard have increased their stakes. Analysts have mixed ratings, with a consensus price target of $45.58. Beam Therapeutics focuses on genetic medicines, with products in clinical trials for diseases like sickle cell and leukemia.

    Market Beat·
    US
    BEAM
    +8.12%
    Market Beat·
    US
    BEAM
    +8.12%

    Beam Therapeutics shares are trading higher after Evercore ISI initiated coverage on the stock with an Outperform rating and announced a $35 price target.

    benzinga_article·
    US
    BEAM
    +8.12%
    benzinga_article·
    US
    BEAM
    +8.12%

    Beam Therapeutics to Join Jefferies London Healthcare Conference

    Beam Therapeutics Inc. will participate in a fireside chat at the 2025 Jefferies London Healthcare Conference on November 19, 2025. A live webcast of the event will be available on the company’s website. This announcement was published via GlobeNewswire on November 12, 2025.

    Reuters·
    US
    BEAM
    +8.12%
    Reuters·
    US
    BEAM
    +8.12%

    Beam Therapeutics: Promising Gene Editing Advances Justify Buy Rating

    JonesTrading analyst Soumit Roy has maintained a Buy rating on Beam Therapeutics (BEAM) due to promising advancements in gene editing technologies, particularly in the Phase 1/2 BEACON trial for sickle cell disease, which achieved a 100% VOE-free rate. The ongoing AATD trials also show potential disease-modifying effects. H.C. Wainwright has similarly reiterated a Buy rating with an $80 price target, reinforcing the positive outlook for Beam's transformative therapies.

    Tip Ranks·
    US
    BEAM
    +8.12%
    Tip Ranks·
    US
    BEAM
    +8.12%

    Cantor Fitzgerald Has Weak Forecast for BEAM FY2025 Earnings

    Cantor Fitzgerald has lowered its FY2025 earnings per share (EPS) estimate for Beam Therapeutics (NASDAQ:BEAM) from ($4.42) to ($4.45). The consensus estimate for the company's current full-year earnings is ($4.57) per share. Cantor Fitzgerald maintains a "Strong-Buy" rating on the stock, while other analysts have varied ratings and price targets. Beam Therapeutics reported a quarterly EPS of ($1.10), missing estimates, with revenue down 32.2% year-over-year. Institutional investors hold 99.68% of the stock, indicating strong institutional interest.

    Market Beat·
    US
    BEAM
    +8.12%
    Market Beat·
    US
    BEAM
    +8.12%
    © 2025 Longbridge｜Disclaimer